Story
Kodiak Sciences Stock Jumps Over 30% on Positive Phase 3 Wet AMD Drug Trial Results
Summary
Shares of Kodiak Sciences surged after the biopharmaceutical company announced positive topline results from its pivotal DAYBREAK Phase 3 study, which evaluated two drug candidates for wet age-related macular degeneration.
Kodiak Sciences (NASDAQ: KOD) stock surged 31.9% in pre-market trading after the company announced positive topline results from its pivotal DAYBREAK Phase 3 clinical trial. The study evaluated two of its investigational therapies for treating patients with wet age-related macular degeneration (wet AMD), a leading cause of vision loss.
Pivotal Study Delivers Positive Results
The DAYBREAK study assessed both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer). According to the company's announcement, the trial met its primary endpoint of non-inferiority in visual acuity gains compared to the active comparator, aflibercept, a widely used treatment for the condition.
Kodiak Sciences hosted a webcast to present the detailed findings. The significant pre-market stock movement indicates strong investor optimism that the data successfully de-risks the clinical profile of both drug candidates.
High Stakes and Market Implications
The trial carried unusually high stakes, as it evaluated two distinct molecules within a single study, potentially unlocking two separate commercial opportunities. A successful outcome positions Kodiak to compete in the retinal vascular disease market, where anti-VEGF therapies generate approximately $15 billion in annual sales.
AdFor Zenkuda, the positive data is particularly significant. The drug already has a Biologics License Application (BLA)-ready profile from previous Phase 3 successes in diabetic retinopathy and retinal vein occlusion. This positive result in wet AMD could complete the regulatory package needed for a broader market submission.
Market Reaction and Context
The sharp rise in Kodiak's shares was a company-specific event, standing in stark contrast to the broader market trend. During the same pre-market session, the Nasdaq fell 1.0% and the S&P 500 declined 0.6%, underscoring that the move was driven entirely by the clinical trial news.
Ahead of the data release, some analysts had maintained a bullish outlook. UBS, for example, had reiterated a Buy rating on the stock with an $80 price target, anticipating that the trial would demonstrate non-inferiority. The positive binary outcome has lifted the stock toward its 52-week high of $47.84.
Read next
More on Stocks
Haleon Placed on Negative Catalyst Watch by J.P. Morgan on Slowing Sales
J.P. Morgan placed consumer health firm Haleon on a negative Catalyst Watch, citing weak sales momentum that threatens the company's growth targets and prompts cuts to earnings forecasts and its price target.
American Express Expands Global Acceptance to 190 Million Merchant Locations
American Express announced its cards are now accepted at over 190 million locations worldwide, with international acceptance more than doubling in four years as it works to close the gap with rivals Visa and Mastercard.
NVIDIA Shares Rise on Record $150 Billion Share Buyback Increase
The chipmaker's stock climbed in pre-market trading after it unveiled the largest-ever increase to a share repurchase program, bringing its total authorization to $235 billion.
PepsiCo Downgraded by Deutsche Bank on Doubts Over North American Recovery
Deutsche Bank cut its rating on PepsiCo to 'Hold' from 'Buy,' citing concerns that the company's turnaround efforts in its food and beverage units are yielding only temporary benefits amid a challenging consumer environment.